Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) EBIT (2020 - 2025)

Historic EBIT for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to -$9.2 million.

  • Cytek Biosciences' EBIT fell 11638.42% to -$9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.8 million, marking a year-over-year decrease of 3450.48%. This contributed to the annual value of -$20.5 million for FY2024, which is 2629.56% up from last year.
  • Cytek Biosciences' EBIT amounted to -$9.2 million in Q3 2025, which was down 11638.42% from -$10.6 million recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' EBIT registered a high of $3.8 million during Q2 2021, and its lowest value of -$15.0 million during Q1 2025.
  • Its 5-year average for EBIT is -$4.0 million, with a median of -$2.4 million in 2022.
  • As far as peak fluctuations go, Cytek Biosciences' EBIT crashed by 92435.47% in 2023, and later surged by 227956.2% in 2024.
  • Quarter analysis of 5 years shows Cytek Biosciences' EBIT stood at $1.3 million in 2021, then tumbled by 93.62% to $84000.0 in 2022, then plummeted by 263.1% to -$137000.0 in 2023, then surged by 2279.56% to $3.0 million in 2024, then crashed by 407.84% to -$9.2 million in 2025.
  • Its EBIT was -$9.2 million in Q3 2025, compared to -$10.6 million in Q2 2025 and -$15.0 million in Q1 2025.